AIM ImmunoTech Announces Filing of Provisional Patent Application for Use of Ampligen as Both an Intranasal and an IV Therapy for Post-COVID-19 Cognitive Dysfunction (PCCD)
Patients with symptoms of PCCD being treated with Ampligen in the ongoing AMP-511 Early Access Program have reported consistent improvements...